Institutional profile: A hub for bench-to-bedside pharmacogenomic-based research

Pharmacogenomics

Volumn 12, Issue 8, 2011, Pages 1095-1098

  Voora, Deepak ^a   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Duke institute for genome sciences policy; Individualized medicine; Pharmacogenetics; Pharmacogenomics; Translational research

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; COLORECTAL CANCER; COPY NUMBER VARIATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; HEPATITIS C; HUMAN; INSTITUTIONALIZATION; INTERDISCIPLINARY RESEARCH; METAGENOMICS; MOLECULAR MODEL; ONCOGENE K RAS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; SCCO1B1 GENE; TOXIC HEPATITIS; TRANSLATIONAL RESEARCH; TUMOR GENE; UGT1A1 GENE; FINANCIAL MANAGEMENT; LABORATORY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ACADEMIES AND INSTITUTES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; INDIVIDUALIZED MEDICINE; LABORATORIES; PHARMACOGENETICS; RESEARCH SUPPORT AS TOPIC; TRANSLATIONAL RESEARCH;

EID: 80155192457     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/PGS.11.62     Document Type: Article

References (7)

1. Voora D, Shah SH, Reed CR et al. Pharmacogenetic predictors of statinmediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet. 1, 100-106 (2008).
2. *5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609-1616 (2009).
3. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts Hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
4. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic Hepatitis C. Nature 464, 405-408 (2010).
5. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
6. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the plato trial. Lancet 376, 1320-1328 (2010).
7. Voora D, Horton JR, Shah SH, Shaw LK, Newby LK. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes during regular aspirin use. Am. Heart J. 162(1), 166-172.e1 (2011).